Daniel Aletaha
Rheumatology · 2005–2022
A researcher in the Science corpus: 18 papers; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Rheumatology — 208 citations into it
- Oncology — 24 citations into it
- Molecular Biology — 19 citations into it
Whom Daniel Aletaha trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Daniel Aletaha overall
Papers from Daniel Aletaha's perspective
Ordered by how strongly the researchers Daniel Aletaha trusts endorse each paper. Same corpus, a different order for every researcher.
- New therapies for treatment of rheumatoid arthritis. (The Lancet)
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled… (Annals of the Rheumatic Diseases)
- Treating rheumatoid arthritis to target: recommendations of an international task force (Annals of the Rheumatic Diseases)
- The measurement of observer agreement for categorical data.
- Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007 (Arthritis & Rheumatism)
- Inflammatory bone loss: pathogenesis and therapeutic intervention (Nature reviews. Drug discovery)
- Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. (American Journal of Medicine)
- Dickkopf-1 is a master regulator of joint remodeling (Nature Medicine)
- Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling (Nature)
- The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. (New England Journal of Medicine)
Their papers
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) — 4,103 citations
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (2022) — 1,431 citations
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (2020) — 807 citations
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) — 2,212 citations
- Rheumatoid arthritis (2018) — 1,770 citations
- Diagnosis and Management of Rheumatoid Arthritis: A Review (2018) — 1,988 citations
- Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2017) — 612 citations
- Rheumatoid arthritis (2016) — 2,112 citations
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update (2015) — 893 citations
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (2015) — 1,399 citations
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) — 1,725 citations
- Treating rheumatoid arthritis to target: recommendations of an international task force (2010) — 2,111 citations
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. (2010) — 7,452 citations
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative (2010) — 4,289 citations
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) — 2,684 citations
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate (2008) — 832 citations
- New therapies for treatment of rheumatoid arthritis. (2007) — 1,029 citations
- The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. (2005) — 935 citations